Skip to main content

RETRACTION article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1506202

Retraction: Mir-124 Attenuates STAT3-Mediated TH17 Differentiation in Colitis-Driven Colon Cancer

Provisionally accepted
Frontiers Editorial Office Frontiers Editorial Office *
  • Frontiers Media SA, Lausanne, Switzerland

This article is a retraction of:

  1. Mir-124 Attenuates STAT3-Mediated TH17 Differentiation in Colitis-Driven Colon Cancer

    1. Read original article

The final, formatted version of the article will be published soon.

    Retraction: Mir-124 Attenuates STAT3-Mediated TH17 Differentiation in Colitis-Driven Colon Cancer Please find the retraction statement below: Lin S, Liu Q, Wen J, Bai K, Guo Y and Wang J (2020) Mir-124 Attenuates STAT3-Mediated TH17 Differentiation in Colitis-Driven Colon Cancer. Front. Oncol. 10:570128. doi: 10.3389/fonc.2020.570128 Following publication, concerns were raised regarding the integrity of the images in the published figures. An investigation by our internal Research Integrity department, conducted in accordance with Frontiers policies, was unable to confirm the validity of the data presented and we cannot vouch for its reliability. The article is therefore retracted. This retraction was approved by the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.

    Keywords: mir-124, stat3, Th17 cell, Colitis, Colitis-related cancer

    Received: 04 Oct 2024; Accepted: 04 Oct 2024.

    Copyright: © 2024 Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.